middle.news
How Tryptamine Therapeutics Is Shaping Psychedelic Medicine Despite $5.3M Loss
3:49am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Tryptamine Therapeutics Is Shaping Psychedelic Medicine Despite $5.3M Loss
3:49am on Saturday 30th of August, 2025 AEST
Key Points
Reported $5.33 million net loss, improved from prior period
Completed Phase 1b trials for IV-infused psilocin (TRP-8803) showing safety and controlled dosing
Positive signal studies for oral psilocybin (TRP-8802) in fibromyalgia and IBS
Secured $6 million placement and $2.6 million R&D loan facility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TYP
OPEN ARTICLE